11.8.1 Tear deficiency, ocular lubricants and astringents
In order of increasing cost:
GREEN Sno-Tears® eye drops
GREEN Hypromellose 0.3% eye drops
GREEN Clinitas Gel® eye drops
Clinitas® UDV 0.4%
GREEN VitA-POS® eye ointment
GREEN Sodium chloride eye drops 0.9%
GREEN llube® eye drops
GREEN Sodium chloride unit dose eye drops 0.9%
Ciclosporin for treatment of dry eye disease that has not improved despite treatment with artificial tears is recommended as an option by NICE. NICE TA369
AMBER Ciclosporin (Ikervis®) unit dose eye drops
Hylo preparations are preservative free and supplied in a unique delivery device that assures 6 month sterility. They are cost effective to use when viability beyond 28 days is required. If being used more frequently the prescriber is reminded to use as second line after other products have been tried and not tolerated.
GREEN Hylo-Tear® eye drops
Hylo-Forte® eye drops
Sodium Chloride 5% eye drops
11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment
Ocular diagnostic preparations
AMBER Apraclonidine eye drops 0.5%
RED Fluorescein unit dose eye drops 1%, 2%
RED Proxymetacaine & fluorescein unit dose eye drops 0.5%
Ocular peri-operative drugs
RED Balanced Salt Solution®
AMBER Diclofenac unit dose eye drops 0.1%
AMBER Ketorolac eye drops 0.5%
RED Miochol-E® solution for intra-ocular irrigation
RED Sodium hyaluronate injection 10mg/ml, 14mg/mL, 23mg/mL
Approved for specific use in ophthalmolgy for volume enhancement of post-enucleation socket syndrome:
RED Hyaluronic acid injection (Restylane Sub-Q,® Juvederm®)
Approved for use in opthalmology for those at higher risk of developing post-surgical cystoid macular oedema:
RED Bromfenac eye drops (Yellox®)
Subfoveal choroidal neovas cullarisation For use as per NICE guidance only.
RED Verteporfin injection 15mg vial
Aflibercept Approved for use in line with NICE guidance
TAG294 Wet age-related macular degeneration
TAG305 Visual Impairment caused by macular oedema secondary to central retinal vein occlusion
TAG 346 Treatment for some people with sight problems caused by diabetic macular oedema
RED Aflibercept solution for intravitreal injection 40mg/mL
Vitreomacular traction Orciplasmin for use in accordance with NICE guidance as an option in NICE TA297
RED Orciplasmin concentrate for solution for intravitreal injection 2.5mg/mL (Each vial contains 0.5 mg of ocriplasmin in 0.2 ml solution)
Ranibizumab Approved for use in accordance with NICE guidance:
TA283 Visual Impairment caused by Macular oedema secondary to retinal vein occlusion
TA274 Diabetic macular oedema (DMO)
TA155 Wet age-related macular degeneration (AMD)
TAG298 Choroidal neovascularisation associated with pathological myopia
RED Ranibizumab solution for intravitreal injection 10mg/mL vial